ClinicalTrials.gg
Not yet recruitingNCT06782048Updated Oct 13, 2026

Use of Pyrvinium to Reverse Stomach Precancerous Conditions

A Phase 2 interventional study of Placebo and Pyrvinium in STOMACH NEOPLASM, sponsored by National University Hospital, Singapore. Not yet recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by National University Hospital, Singapore · Phase 2, Interventional, and Treatment

How we know

Updated Oct 13, 2026Start date movedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Stomach Neoplasms by National University Hospital, Singapore — 5 open to participants now, 8 under way, 1 of them phase 3. Stomach Neoplasms · National University Hospital, Singapore.

Planned enrollment
6th of 17
50 · median 30
Started
2026
with 2 others
Phase 2
7 of 24
1 open now
Registered
23rd of 24
by date

Among the 24 studies in Stomach Neoplasms by National University Hospital, Singapore, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 2, and was the 23rd registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

5 of the 24 studies in Stomach Neoplasms by National University Hospital, Singapore are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Stomach Neoplasms by National University Hospital, Singapore, or all of them as a file.
02

Study summary

This study is carried out to find out if a drug called pyrvinium is able to convert pre-cancerous tissue in the stomach back to healthy tissue, to lower the chances of stomach cancer. Pyrvinium is a drug that has been used for a long time to treat pinworms in children and its anti-cancer properties are currently under investigation. Tests in animals have shown that pyrvinium made unhealthy tissue healthier and stopped some cells from growing in a bad way. Based on preclinical studies, the investigators hypothesise that the proportion of samples with pre-cancerous tissue in the stomach would decrease by 30% after exposure to pyrvinium at the 6-week timepoint, with anticipated durability of the response at the one-year follow-up.

Read the detailed description

Objectives:

The main objectives of the study are to gain additional data on the efficacy and safety for the use of pyrvinium in human participants with gastric intestinal metaplasia and/or dysplasia for reversion to complete intestinal metaplasia or normal gastric mucosa. The secondary objectives are to determine the surface area of GIM involvement, evaluate effectiveness of pyrvinium treatment in human pre-cancerous gastroids derived from patients with metaplasia and/or dysplasia, determine targeted effects of pyrvinium treatment in heterogeneous pre-cancerous cells, define functional mechanisms of pyrvinium action as an anti-cancer drug, determine effects of pyrvinium on the level of serum biomarkers associated with GC risk prediction and investigate the impact of pyrvinium on the gastric microbiome.

Study Design:

This is a phase 2 randomized clinical trial which aims to recruit 50 participants with extensive/marked intestinal metaplasia (IM) and/or dysplasia. After enrolment, a baseline oesophagogastroduodenoscopy (OGD) is performed using a modified Cambridge protocol to ensure adequate sampling. As most participants will be recruited prior to confirming their histology at baseline, some participants will be withdrawn from the study if they are detected to have no IM, no extensive/marked IM, or no dysplasia at baseline. 50 participants with evidence of extensive/marked gastric IM and/or dysplasia will receive pyrvinium (2mg/kg/day) or placebo orally in a 1:1 randomization ratio daily for a period of 14 days. Participants will be followed up at the clinic for monitoring of symptoms at Day 14 of treatment. Participants will remain blinded, and study team will be split into blinded and unblinded teams. Only the unblinded team will have access to exposure (pyrvinium vs placebo) during the active phase of the trial. In total, there will be 3 follow-up study visits at the clinic after randomization, for up to a year after the last day of treatment.

Baseline:

Participants will undergo a baseline OGD and biopsy to ascertain IM and dysplasia status. Gastric mucosal biopsies will be collected as follows:

  • 1 biopsy each from AL, AG, IA, BL, BG, PP and sent for histological examination
  • 3 adjacent biopsies at BL, 1 biopsy at IA, 5 adjacent biopsies at AL, 1 biopsy at AG and 2 adjacent biopsies at PP, will be snap-frozen in liquid nitrogen

The locations are defined as follows:

  • AL - lesser curvature of the antrum, within 2-3cm of the pylorus
  • AG - greater curvature of the antrum, within 2-3cm of the pylorus
  • IA - incisura angularis
  • BL - lesser curvature of the corpus, 4cm proximal to the angulus
  • BG - middle portion of the greater curvature of the corpus, 8cm from the cardia
  • PP - prepylorus

Gastric juice will be taken if there is an opportunity to do so, and gastric pH will be measured. 4 biopsies of areas of known gastric IM will be used to generate gastric organoids. Participants with evidence of extensive/marked gastric IM and/or dysplasia will then be randomized to either the pyrvinium or placebo treatment arm. Clinical data including co-morbidities, medication use, H. pylori testing and treatment history, family history, tobacco and alcohol exposures, endoscopic data, and pathology/histology results will be collected at the time of enrolment.

The initial IM lesion area is located by targeting EGGIM II, which correlates well with extensive IM. The gastric mucosa is observed with HD-WLE followed by HD-NBI. The OGD procedure will be recorded for verification purposes. All mucosal lesions identified during OGD will be biopsied separately as a part of normal clinical practice and sent for histopathological assessment. Frozen biopsy samples will be stored at a high-quality tissue bank. Investigators will follow the above protocol. However, they may deviate from protocol if the interests of the patient require so.

Histological Assessment:

For histological evaluation, biopsies will be stained for H\&E as well as PAS/Alcian blue. In addition, immunostaining will be performed for markers of normal gastric lineages, metaplasia (SPEM and IM) and dysplasia. Marker expression in biopsies will be evaluated with digital imaging and quantitation.

Food Frequency Questionnaire (FFQ):

Participants will be asked to complete an FFQ once at the baseline visit, within 4 weeks from the stool sample collection.

Follow-up:

Both pyrvinium and placebo groups will undergo the same follow-up procedures. Mucosal biopsies will be collected at each of the follow-up surveillance OGDs as follows:

  • 1 biopsy each from AL, AG, IA, BL, BG, PP and sent for histological examination
  • 2 adjacent biopsies at BL, 4 adjacent biopsies at AL and 2 adjacent biopsies at PP will be snap-frozen in liquid nitrogen

A maximum of 14 research biopsies will be taken at each of the follow-up endoscopies. The EGGIM score will be recorded. The gastric mucosa is observed with HD-WLE followed by HD-NBI. The OGD procedure will be recorded for verification purposes. All mucosal lesions identified during OGD will be biopsied separately as a part of normal clinical practice and sent for histopathological assessment. Frozen biopsy samples will be stored at a high-quality tissue bank. Investigators will follow the above protocol. However, they may deviate from protocol if the interests of the patient require so.

Follow-up surveillance OGDs will be done at Day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment. A window period of ± 2 days for the surveillance OGD at Day 7 of treatment, and ± 2 weeks for the surveillance OGD at 6 weeks and 1-year post-treatment are acceptable.

Symptoms will be monitored via clinic on the last day of the treatment (Day 14). Known rare side-effects include skin rash, sun-sensitivity, diarrhoea, nausea/vomiting, stomach cramps and these and other symptoms will be monitored in all subjects.

Blood Collection, Processing and Analyses:

Up to 20ml of blood will be drawn from each participant at each of the following timepoints: baseline, day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment. The serum, plasma and buffy coat will be extracted.

Gastric Juice, Saliva and Stool Collection:

Gastric juice will be taken, and gastric pH will be measured at each research endoscopy, i.e., baseline, day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment. Saliva and stool will also be obtained from participants at research endoscopy for microbiome studies at the following timepoints: baseline, day 7 of treatment, 6 weeks post-treatment, and 1 year post-treatment.

Human Pre-cancer Organoids:

The investigators will perform biological studies using human organoids derived from patients recruited for the phase 2 clinical trial, with the aim of determining targeted effects of pyrvinium treatment in heterogeneous pre-cancerous cells and define functional mechanisms of pyrvinium action as an anti-cancer drug.

Serum Biomarker Profiling:

Total RNA from serum is isolated and converted to cDNA, which is then quantified. Target miRNA expression levels after normalization of both technical and biological variations are analysed to identify panels of miRNAs with the highest discriminatory power between healthy and disease states.

Microbiota Analyses:

Tissues, gastric juice, saliva and stool will undergo next generation metagenomic sequencing and directed culturomics, to study microbe-host interactions in IM progression/regression.

Single Cell Analysis:

Tissues will be placed into cold tissue storage solution and dissociated into single cells using enzymatic digestion and trypan blue staining will be performed to determine cell viability. Dissociated cells will then be used for various single cell platforms such as scRNA-seq, scDNA-seq, scATAC-seq, single-cell immune profiling and other single-cell related technologies (accompanied by in- depth integrative computational data analysis) to determine the respective biological measurements. In addition to this, tissues might also be used for several genomic platforms (eg. exome sequencing and low pass sequencing etc) and immunohistological platforms.

Sample Size Calculation:

A sample size of 48 participants (24 per group) will be required to detect a difference of 30% in proportion of participants with a reduction in gastric intestinal metaplasia (primary endpoint) between the treatment (Pyrvinium) and control (Placebo) groups to achieve 80% power at 20% one-side type-I error rate, assuming close to 0% participants will have any reduction in gastric intestinal metaplasia, and 20% potential drop-out rate. The study design is referred to as Phase II Screening Trial Design, which has 80% chance to detect the treatment is truly effective and worth investigating further in a Phase III trial if the study results favourable to the treatment. The recruitment target has been rounded up from 48 to 50 participants.

Statistical Analysis:

(A) General considerations

The investigators hypothesise that pyrvinium (oral 2mg/kg/day for 14 days) compared to the control placebo would result in an absolute 30% reduction in gastric IM, whereby our advanced gastric IM patients have a mean 75.6% +/- 8.4%(SD) presence of IM in their biopsies compared to mild gastric IM patients with a mean 14% +/- 8.2%(SD) presence of IM in their gastric biopsies.

Continuous variables will be summarized using descriptive statistics including means, medians, Q1 and Q3, minimum and maximum, and standard deviations. Categorical variables will be summarized using percentages and frequencies. All confidence intervals are 95%.

(B) Efficacy analyses

All efficacy analysis will be performed based on the intention-to-treat population. The primary endpoint of percentage of patients with a reduction in gastric intestinal metaplasia (and/or dysplasia for reversion to complete intestinal metaplasia or normal gastric mucosa) will be calculated for the treatment and placebo group separately. The difference in the percentage will be presented along with 95% exact confidence interval. No p-values will be reported considering exploratory nature of the study. Secondary endpoints with binary outcomes will be analysed similar to the primary endpoint. Secondary continuous endpoints will be presented as mean change from baseline at the follow-up time-points. The difference in mean values between the groups will be presented at each follow-up time-point along with their 95% confidence intervals.

(C) Safety analyses

All safety analysis will be presented based on the treated population. Adverse and serious adverse events will be presented with number of subjects experiencing each type of adverse events and serious adverse events along with their relationship with the group and severity using counts and percentages. Laboratory results will be presented with their mean values at each assessment time-points along with the percentage of abnormal and clinically significant results for each group.

(D) Interim analyses

There is no formal interim analysis planned. However, the Principal Investigator, supported by delegated medically qualified study team members, will regularly review individual and cumulative safety data, including AEs, SAEs, clinically significant laboratory abnormalities, and study procedure-related events. Any emerging safety concerns will be promptly assessed. Based on the cumulative safety findings, the PI will determine whether additional safety measures or protocol amendments are required.

03

Conditions studied

  • STOMACH NEOPLASM

Browse trials for

Keywords

  • Gastric Cancer
  • Stomach Neoplasm
  • Intestinal Metaplasia
  • Pyrvinium
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is at least 21 years of age.
  • The subject has proven extensive/marked intestinal metaplasia and/or dysplasia. Extensive/ marked IM is defined by: (a) Presence of multifocal IM (IM present in antrum and body), and (b) At least one with at least moderate IM severity.
  • The subject is willing and able to provide signed and dated patient form indicating that he/she has been informed of all pertinent aspects of the study.

Exclusion criteria

Exclusion Criteria:

  • The subject has an active gastric cancer diagnosis.
  • The subject has a personal history of gastric cancer diagnosis.
  • The subject has a previous total or partial gastrectomy.
  • The subject is pregnant (positive urine pregnancy test).
  • The subject has a high-risk of bleeding complications due to anticoagulants or underlying medical condition such as bleeding disorders in whom are .
  • The subject has impaired renal function, defined as an estimated (eGFR) of less than 60 mL/min/1.73m² (eGFR \<60).
  • The subject has impaired hepatic function, defined as any of the following laboratory abnormalities: (ALT) > 100 U/L, Aspartate aminotransferase (AST) > 100 U/L, Total (Bil) > 50 µmol/L, Albumin \< 30 g/L.
  • The subject has known to any components of the study product such as sucrose, benzyl alcohol, or propylene glycol .
  • The subject has chronic bowel disease, (defined as Crohn's disease, ulcerative colitis and/or inflammatory bowel disease).
  • The subject has any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may interfere with the interpretation of study results and in the judgement of the investigator would make the subject unsuitable for entry into the study.
  • The subject on regular anti-coagulant prophylaxis such as warfarin must be able to undergo a 5-day before each gastroscopy. The subject on aspirin, ticlopidine and clopidogrel must be able to undergo a one-week washout period before each gastroscopy. The subject's physician or study co-investigator will exercise their clinical judgement to ensure subject's safety.
  • The subject is unwilling or unable to provide signed .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Pyrvinium

    Pyrvinium will be administered to participants.

    Drug: Pyrvinium · Procedure: Blood biomarkers analyses · Procedure: Oesophagogastroduodenoscopy (OGD) and biopsy · Other: Gastric juice, saliva and stool collection and analyses

  • Placebo comparator
    Placebo

    Placebo will be administered to participants.

    Drug: Placebo · Procedure: Blood biomarkers analyses · Procedure: Oesophagogastroduodenoscopy (OGD) and biopsy · Other: Gastric juice, saliva and stool collection and analyses

Interventions

  • DrugPlacebo

    Participants will receive placebo by mouth once each day for a total of 14 days.

  • Participants will receive pyrvinium (2 mg/kg/day) by mouth once each day for a total of 14 days.

  • ProcedureBlood biomarkers analyses

    Up to 20ml of blood will be drawn from each participant at each study visit, with a total of 4 study visits for molecular analyses.

  • ProcedureOesophagogastroduodenoscopy (OGD) and biopsy

    Study participant will undergo OGD with collection of gastric mucosal biopsies at the baseline visit to ascertain IM status and for molecular analyses. Study participant will undergo follow-up gastroscopy with collection of gastric mucosal biopsies at day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment to assess if endpoint is reached and for molecular analyses. Gastric juice samples will be collected during each OGD.

  • OtherGastric juice, saliva and stool collection and analyses

    Gastric juice will be taken, and gastric pH will be measured at each research endoscopy. Saliva and stool will also be obtained from participants at research endoscopy for microbiome studies at the following timepoints: baseline, 6 weeks post-treatment, and 1 year post-treatment.

06

What researchers measure

Primary outcomes

  1. Histological Regression of GIM: Average percentage change of GIM in the antrum and corpus, as measured by histological evaluation of gastric biopsies at baseline and the study endpoint

    Time frame: Baseline, 6 weeks post-treatment

Secondary outcomes

  1. Surface Area of GIM Involvement: Measured in real-time using AI-guided imaging technology during endoscopy

    Time frame: During endoscopy at baseline, Day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment

  2. Safety: Number of participants with treatment-related adverse events

    Time frame: From Day 1 to Day 14 of treatment

  3. Efficacy in Patient-Derived Gastroids: Changes in phosphorylation levels of proteins in pre-cancerous gastroids derived from participants with GIM or dysplasia

    A maximum of 18 research biopsies will be taken at the baseline endoscopy, of which 4 biopsies of areas of known gastric IM will be used to generate gastric organoids.

    Time frame: Baseline

  4. Efficacy in Patient-Derived Gastroids: Evaluation of growth and proliferation after pyrvinium treatment via imaging, staining and histological techniques

    A maximum of 18 research biopsies will be taken at the baseline endoscopy, of which 4 biopsies of areas of known gastric IM will be used to generate gastric organoids.

    Time frame: Baseline

  5. Mechanistic Insights into Pyrvinium Action: Gene expression profiles (e.g., mucins MUC1, MUC2, MUC5AC) in biopsied gastric samples obtained during endoscopy

    Time frame: Baseline, Day 7, 6 weeks post-treatment, 1 year post-treatment

  6. Serum Biomarkers for Gastric Cancer Risk: Levels of serum biomarkers such as TFF3, a known marker for gastric IM, measured via ELISA

    Time frame: Baseline, Day 7 of treatment, 6 weeks post-treatment, 1 year post-treatment

  7. Impact on Gastric Microbiome: Changes in gastric microbiome composition post-treatment, analyzed using advanced sequencing methods

    Time frame: Baseline, 6 weeks post-treatment, 1 year post-treatment

07

Study locations

1 site
  • National University Hospital
    Singapore, 122107, Singapore
    • Jonathan Wei Jie Lee, MBBS, MRCP, MCI · Contactjonathanlee@nus.edu.sg · +6567723951
    • Jonathan Wei Jie Lee, MBBS, MRCP, MCI · Principal investigator
    • Jimmy Bok Yan So, MBChB, FRCSEd, FRCSG, MPH · Sub investigator
    • Wei Peng Yong, MBChB, MRCP · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2029, 37 months later.

Of 296 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 37 months is below that.

Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

Start moved once since we started tracking on Sep 25, 2026: Aug 2025 → Nov 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Jan 17, 2025
StartEst.
Nov 2026was Aug 2025
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2025→Nov 2026
Oct 13, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited, 7 added, 4 removed
What changed in the criteria
Inclusion criteria
  • ChangedBefore The subject has histologically proven extensive/marked intestinal metaplasia and/or dysplasia.Now The subject has histologically proven extensive/marked intestinal metaplasia and/or dysplasia. Extensive/ marked IM is defined by: (a) Presence of multifocal IM (IM present in antrum and body), and (b) At least one biopsy with at least moderate IM severity.
Exclusion criteria
  • AddedThe subject has a personal history of gastric cancer diagnosis.
  • AddedThe subject has a previous total or partial gastrectomy.
  • EditedThe subject is pregnant (positive urine pregnancy test).
  • RemovedThe subject has impaired renal function.
  • RemovedThe subject has impaired hepatic function.
  • RemovedThe subject has fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency.
  • RemovedThe subject has chronic bowel disease.
  • AddedThe subject has impaired renal function, defined as an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73m² (eGFR <60).
  • AddedThe subject has impaired hepatic function, defined as any of the following laboratory abnormalities: Alanine aminotransferase (ALT) > 100 U/L, Aspartate aminotransferase (AST) > 100 U/L, Total bilirubin (Bil) > 50 µmol/L, Albumin < 30 g/L.
  • AddedThe subject has known hypersensitivity to any components of the study product such as sucrose, benzyl alcohol, or propylene glycol .
  • AddedThe subject has chronic bowel disease, (defined as Crohn's disease, ulcerative colitis and/or inflammatory bowel disease).
  • AddedThe subject on regular anti-coagulant prophylaxis such as warfarin must be able to undergo a 5-day washout period before each gastroscopy. The subject on aspirin, ticlopidine and clopidogrel must be able to undergo a one-week washout period before each gastroscopy. The subject's physician or study co-investigator will exercise their clinical judgement to ensure subject's safety.
Oct 13, 2026
Sponsor
Collaborators added: National University of Singapore; collaborators removed: National University Cancer Institute, Singapore
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Start date Aug 2025→Nov 2026
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited, 7 added, 4 removed
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore The subject has histologically proven extensive/marked intestinal metaplasia and/or dysplasia.Now The subject has histologically proven extensive/marked intestinal metaplasia and/or dysplasia. Extensive/ marked IM is defined by: (a) Presence of multifocal IM (IM present in antrum and body), and (b) At least one biopsy with at least moderate IM severity.
    Exclusion criteria
    • AddedThe subject has a personal history of gastric cancer diagnosis.
    • AddedThe subject has a previous total or partial gastrectomy.
    • EditedThe subject is pregnant (positive urine pregnancy test).
    • RemovedThe subject has impaired renal function.
    • RemovedThe subject has impaired hepatic function.
    • RemovedThe subject has fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency.
    • RemovedThe subject has chronic bowel disease.
    • AddedThe subject has impaired renal function, defined as an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73m² (eGFR <60).
    • AddedThe subject has impaired hepatic function, defined as any of the following laboratory abnormalities: Alanine aminotransferase (ALT) > 100 U/L, Aspartate aminotransferase (AST) > 100 U/L, Total bilirubin (Bil) > 50 µmol/L, Albumin < 30 g/L.
    • AddedThe subject has known hypersensitivity to any components of the study product such as sucrose, benzyl alcohol, or propylene glycol .
    • AddedThe subject has chronic bowel disease, (defined as Crohn's disease, ulcerative colitis and/or inflammatory bowel disease).
    • AddedThe subject on regular anti-coagulant prophylaxis such as warfarin must be able to undergo a 5-day washout period before each gastroscopy. The subject on aspirin, ticlopidine and clopidogrel must be able to undergo a one-week washout period before each gastroscopy. The subject's physician or study co-investigator will exercise their clinical judgement to ensure subject's safety.
    Sponsor Collaborators added: National University of Singapore; collaborators removed: National University Cancer Institute, Singapore
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06782048
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Nov 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Jonathan Wei Jie Lee, MBBS, MRCP, MCI
Contact
jonathanlee@nus.edu.sg
+6567723951

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pyrvinium

Start the discussion